Last reviewed · How we verify
Comparator: M-M-R II
M-M-R II is a live attenuated viral vaccine that stimulates immune response against measles, mumps, and rubella by introducing weakened forms of these viruses.
M-M-R II is a live attenuated viral vaccine that stimulates immune response against measles, mumps, and rubella by introducing weakened forms of these viruses. Used for Prevention of measles, mumps, and rubella in children and adults.
At a glance
| Generic name | Comparator: M-M-R II |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains live but weakened (attenuated) strains of measles, mumps, and rubella viruses. When administered, these attenuated viruses replicate in the body at low levels, triggering both humoral (antibody) and cell-mediated immune responses without causing disease. This generates protective immunity against natural infection with these three viruses.
Approved indications
- Prevention of measles, mumps, and rubella in children and adults
Common side effects
- Fever
- Rash
- Parotitis (mumps-like symptoms)
- Arthralgia/arthritis
- Thrombocytopenia
- Encephalitis
Key clinical trials
- A Pilot Study to Evaluate the Therapeutic Efficacy of Intra-Lesional Immunotherapy in Patients Aged 10-60 Years With Recalcitrant Tinea Cruris and Corporis (NA)
- Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) (PHASE3)
- Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026) (PHASE3)
- Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella (PHASE2, PHASE3)
- Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM (PHASE3)
- Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed) (PHASE3)
- Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED) (PHASE2)
- Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comparator: M-M-R II CI brief — competitive landscape report
- Comparator: M-M-R II updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI